Бронхіальна астма - Міністерство охорони здоров'я України

sign.ac.uk/guidelines/published/support/guideline63/index.html314. Pharmacological management of asthma. Evidence table 4.11c: Add-on drugs for inhaled steroids:anticholinergics. Edinburgh: SIGN; 2002. Available from url:http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html315. Pharmacological management of asthma. Evidence table 4.11a: Addon drugs for inhaled steroids:cromones. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html316. Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist:double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol1989;84(6Pt 1):891-5.317. Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit CareMed 2001;164(6):923-32.318. Pharmacological management of asthma. Evidence table 4.22: Combined therapy of inhaled steroidsand long acting B2 agonists. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html319. Pharmacological management of asthma. Evidence table 4.8c: Children with poor asthma control onICS - is addition of leukotriene receptor antagonists helpful? Edinburgh: SIGN; 2002. Available from url:http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html320. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, aleukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.Pediatrics 2001;108(3):E48.321. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults (CochraneReview). In: The Cochrane Library, Issue 3, 2004. London: John Wiley & Sons Ltd.322. British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London inassociation with the General Practitioner in Asthma Group, The British Association of Accident andEmergency Medicine, The British Paediatric Respiratory Society, Royal College of Paediatrics and ChildHealth. The British guidelines on asthma management 1995 review and position statement. Thorax1997;52(Suppl 1):S1-S21.323. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al. Effect ofbudesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract2007;61(5):725-36.324. O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterolcombination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med2005;171(2):129-36.325. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combinationwith formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.Lancet 2006;368(9537):744-53.326. Scicchitano. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher doseof budesonide in moderate to severe asthma. Current Medical Research and opinions 2004;20(9):1403-18.327. Vogelmeier C, D’Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al. Budesonide/formoterolmaintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26(5):819-28.328. National Osteoporosis Society. Guidance on the prevention and management of corticosteroid inducedosteoporosis. Bath: National Osteoporosis Society; 1998.329. Nassif EG, Weinberger M, Thompson R, Huntley W. The value ofmaintenance theophylline in steroiddependentasthma. N Engl J Med 1981;304(2):71-5.330. Pharmacological management of asthma. Evidence table 4.13a:Immunosuppresive agents. Edinburgh:SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html331. O’Driscoll BR, Ruffles SP, Ayres JG, Cochrane GM. Long term treatmentof severe asthma withsubcutaneous terbutaline. Br J Dis Chest1988;82(4):360-7.332. Payne D, Balfour-Lynn I, Biggart E, Bush A, Rosenthal M. Subcutaneous terbutaline in children withchronic severe asthma. Pediatr Pulmonol. 2002;33(5):356-61.333. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumornecrosis factor alpha in refractory asthma N Engl J Med. 2006;354(7):697-708.242